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ABSTRACT
The orphan receptor GPR17 has been reported to be activated
by UDP, UDP-sugars, and cysteinyl leukotrienes, and coupled
to intracellular Ca21 mobilization and inhibition of cAMP accumu-
lation, but other studies have reported either a different agonist
profile or lack of agonist activity altogether. To determine if GPR17
is activated by uracil nucleotides and leukotrienes, the hemagglutinin-
tagged receptor was expressed in five different cell lines and
the signaling properties of the receptor were investigated. In C6,
1321N1, or Chinese hamster ovary (CHO) cells stably expressing
GPR17, UDP, UDP-glucose, UDP-galactose, and cysteinyl
leukotriene C4 (LTC4) all failed to promote inhibition of
forskolin-stimulated cAMP accumulation, whereas both UDP and
UDP-glucose promoted marked inhibition (.80%) of forskolin-
stimulated cAMP accumulation in C6 and CHO cells expressing
the P2Y14 receptor. Likewise, none of these compounds pro-
moted accumulation of inositol phosphates in COS-7 or
human embryonic kidney 293 cells transiently transfected
with GPR17 alone or cotransfected with Gaq/i5, which links Gi-
coupled receptors to the Gq-regulated phospholipase C (PLC)
signaling pathway, or PLC«, which is activated by the Ga12/13
signaling pathway. Moreover, none of these compounds pro-
moted internalization of GPR17 in 1321N1-GPR17 cells. Con-
sistent with previous reports, coexpression experiments of
GPR17 with cysteinyl leukotriene receptor 1 (CysLTR1) sug-
gested that GPR17 acts as a negative regulator of CysLTR1.
Taken together, these data suggest that UDP, UDP-glucose,
UDP-galactose, and LTC4 are not the cognate ligands of
GPR17.
Introduction
Extracellular adenine and uracil nucleotides regulate a
broad range of physiologic and pathophysiological responses
by activating two main receptor families: P2X receptors,
which are ATP-gated cation-selective ion channels; and P2Y
receptors, which are G protein–coupled receptors (GPCRs)
activated by adenine and uracil nucleotides. To date, molecular
cloning and pharmacological characterization have identified
seven mammalian P2X receptors (P2X1–7) and eight func-
tional mammalian P2Y receptor subtypes (P2Y1, P2Y2, P2Y4,
P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14) (Costanzi et al., 2004;
Abbracchio et al., 2006). Based on their sequence identity and
signaling properties, P2Y receptors are commonly grouped into
two subfamilies. The P2Y1 receptor subfamily, which encom-
passes P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 receptors, couples
to Gq and activates phospholipase C (PLC). In addition to
coupling to Gq, the P2Y11 receptor also couples to Gs and
activates adenylyl cyclase, albeit with lower efficiency than
Gq/PLC (Qi et al., 2001a; Torres et al., 2002). The P2Y12
receptor subfamily members, which include P2Y12, P2Y13,
and P2Y14, are all located in a gene cluster on chromosome 3,
share ∼43–47% sequence identity, and couple to Gi/o. An ad-
ditional receptor in this cluster, GPR87, which shares∼34–42%
identity with the other P2Y receptors, apparently is not ac-
tivated by nucleotides but has been reported to be activated by
lysophosphatidic acid (Tabata et al., 2007).
Erroneous designation of new or orphan receptors as P2Y
receptors has caused considerable confusion and controversy.
Seven receptors (p2y3, p2y5, p2y7, p2y8, p2y9, p2y10, and
p2y15) were originally classified as P2Y receptors (Akbar
et al., 1996; Webb et al., 1996a,b; Bogdanov et al., 1997; Inbe
et al., 2004), but were later shown either to not respond to
nucleotides (p2y5, p2y7, p2y9, p2y10, and p2y15) (Herold
et al., 1997; Janssens et al., 1997; Li et al., 1997; Qi et al.,
2004) or likely to be species homologs of mammalian P2Y
receptors (i.e., the avian P2Y3 receptor and mammalian P2Y6
receptors; the Xenopus P2Y8 and mammalian P2Y4 receptors)
(Li et al., 1998). Several of the aforementioned receptors were
deorphaned and shown to respond to either leukotriene B4
(p2y7) (Yokomizo et al., 1997), lysophosphatidic acid (p2y5,
p2y9, and p2y10) (Noguchi et al., 2003; Murakami et al., 2008;
Pasternack et al., 2008), sphingosine 1-phosphate (p2y10)
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(Murakami et al., 2008), or the citric acid cycle metabolite
a-ketoglutarate (p2y15) (He et al., 2004; Qi et al., 2004).
An orphan GPCR, GPR17, which is located phylogenetically
at an intermediate position between P2Y and cysteinyl leu-
kotriene receptors (CysLTRs), was reported to be activated
by cysteinyl leukotrienes, uracil nucleotides, and nucleotide
sugars (UDP, UDP-glucose, and UDP-galactose) and promote
mobilization of intracellular Ca21 and inhibition of cAMP
accumulation (Ciana et al., 2006). Although multiple follow-up
studies consistent with this original report have been pub-
lished by the same group (Parravicini et al., 2008; Pugliese
et al., 2009; Buccioni et al., 2011; Daniele et al., 2011; Coppi
et al., 2013), Benned-Jensen and Rosenkilde (2010) reported
that UDP and UDP-glucose, but not cysteinyl leukotrienes,
promoted GPR17-dependent guanosine 59-O-(3-[35S]thio)tri-
phosphate binding, and Maekawa et al. (2009) concluded
that GPR17 was not activated by any of these presumed
agonists but instead was a negative regulator of CysLTR1.
Given these disparate results, we have reexamined the po-
tential activation of GPR17 in a broad range of cell types
that either stably or transiently express this GPCR. In ad-
dition, four independent downstream signaling responses
were quantified in response to uracil nucleotides, nucleotide
sugars, or cysteinyl leukotrienes. Our data indicate that
GPR17 is neither activated nor internalized by these ligands,
whereas receptors that are established targets of these
ligands demonstrate robust activation and internalization.
Moreover, our data are consistent with GPR17 acting as a
negative regulator of CysLTR1 as reported previously (Maekawa
et al., 2009).
Materials and Methods
All cell culture reagents were supplied by the Lineberger Com-
prehensive Cancer Center tissue culture facility (University of North
Carolina at Chapel Hill). UDP, UDP-glucose, UDP-galactose, cysteinyl
leukotriene C4 (LTC4), 3-isobutyl-1-methyl-xanthine, and carbachol
were from Sigma-Aldrich (St. Louis, MO). ATP and FuGENE6 trans-
fection reagent were from Roche (Indianapolis, IN). Forskolin was
purchased from Calbiochem (La Jolla, CA). CysLTR1 [3 hemagglu-
tinin (HA)-tagged CysLTR1 in pcDNA3.1(1)] was obtained from the
cDNA Resource Center at the Missouri University of Science and
Technology (Rolla, MO).
Construction of HA-Tagged GPR17 cDNAs. The coding se-
quence of the short form of GPR17 was amplified from human
genomic DNA by polymerase chain reaction with Pfu polymerase
(Stratagene, Carlsbad, CA). The upstream primer sequence con-
tained an MluI site at its 59 end (59-TGACGCGTCCAATGGCCTT-
GAAGTGGCTCC-39), while the downstream primer contained an
XhoI site following the stop codon (59-TCCTCGAGCTACAGCTCT-
GACTTGGCA-39). The amplified fragment was digested with MluI
andXhoI and ligated in-frame into a similarly digested pLXSN retroviral
expression vector containing an EcoRI site, Kozak initiation sequence,
initiating methionine residue, and the HA epitope tag (YPYDVPDY),
followed by an MluI site. To construct pcDNA3-HA-GPR17, pLXSN-
HA-GPR17 was digested with EcoRI and XhoI and ligated in-frame
into similarly digested pcDNA3 expression vector. The sequence of
GPR17 was identical to accession #NP_001154888.1.
Stable Expression of GPR17 and Other GPCRs in 1321N1,
Chinese Hamster Ovary, and C6 Cells. Stable expression of
GPR17 in 1321N1, Chinese hamster ovary (CHO), and C6 cells was
accomplished by retroviral infection as described previously (Qi et al.,
2001a). Briefly, recombinant retrovirus particles were produced by
calcium phosphate–mediated transfection of PA317 cells with pLXSN
alone or with pLXSN containing HA-tagged versions of GPR17, P2Y6,
P2Y14, cysteinyl leukotriene receptor-1 (CysLTR1), or lysophosphati-
dic acid receptor-3 (LPA3) receptors. Recombinant retroviruses were
harvested 2 days later and incubated with 1321N1, CHO, and C6 cells
in the presence of 8 mg/ml hexadimethrine bromide (Polybrene). After
2 days, G418-resistant cells were selected with 1 mg/ml G418-containing
medium.
Transient Expression of GPR17 and Other GPCRs in COS-7
and Human Embryonic Kidney 293 Cells. Transient trans-
fections were performed with FuGENE6 according to the manufac-
turer’s protocol. Briefly, 1  106 COS-7 or human embryonic kidney
(HEK) 293 cells per 60-mm dish were incubated with 8 ml of FuGENE6
and 2.8 mg pcDNA3-based plasmid construct in 0.4 ml of serum-free
Dulbecco’s modified Eagle’s medium (DMEM). For cotransfection
experiments with Gaq/i5, 2 mg of receptor DNA and 0.8 mg of pcDNA1-
Gaq/i5 DNA (Conklin et al., 1993) per dish were used. Following
overnight incubation, the cells were treated with trypsin and plated in
24-well dishes for activity assays carried out 2 days later.
Expression of HA-Tagged CysLTR1. The pcDNA3.1 expression
plasmid for human CysLTR1 obtained from the cDNA Resource
Center has three consecutive HA tags fused to the amino terminus of
the receptor. This vector was used to transiently transfect COS-7 and
HEK293 cells, but cell surface expression was not detected by
radioimmunoassay (RIA) in two independent transfections. A pre-
vious study demonstrated that surface expression of mouse CysLTR1
could be improved by fusing a cleavable signal sequence to the amino
terminus of the receptor (Martin et al., 2001). Therefore, we made
a new construct by fusing the 16-amino-acid prolactin signal sequence
(Guan et al., 1992) to the start of the 3 HA tag of the receptor, and
significant cell surface expression was demonstrated when this plas-
mid was transfected into COS-7 and HEK293 cells. For stable expres-
sion in 1321N1 and CHO cells, the fragment encoding the receptor
fused to the prolactin signal sequence was subcloned into pLXSN and
the receptor was expressed by retroviral infection as described
above.
Assay of Inositol Phosphate and cAMP Accumulation. 1321
N1 and CHO cells were seeded in 24-well plates at 105 and 5  104
cells/well, respectively, and assayed 3 days later when confluent.
Transiently transfected COS-7 and HEK293 cells were seeded in
24-well plates at 2  105 cells/well and assayed 2 days later. Inositol
lipids were radiolabeled by overnight incubation of cells with 200 ml
serum-free, inositol-free DMEM containing 0.4 mCi myo-[3H]inositol.
Agonists or antagonists were added at 5 concentration in 50 ml of
50 mM LiCl and 250 mM HEPES, pH 7.25. Following a 30-minute
incubation (10 minutes in Fig. 3) at 37°C, the medium was aspirated
and the reaction was terminated by adding 0.75 ml boiling EDTA,
pH 8.0. [3H]Inositol phosphates were resolved on Dowex AG1-X8
(Sigma-Aldrich) columns as described previously (Qi et al., 2001a).
To quantify cAMP accumulation, cells were labeled with 200 ml
serum-free DMEM containing 0.8 mCi of [3H]adenine for 2 hours. Ten
minutes prior to the assay, cells were supplemented with 50 ml of
40 mM HEPES, pH 7.4, and 200 mM isobutyl methylxanthine (final
concentrations in the assay). Drugs were added at 6 concentration in
50 ml of Hanks’ balanced salt solution (HBSS) for 30 minutes at 37°C.
Reactions were terminated by aspiration of the medium and addition
of 1 ml of 5% trichloroacetic acid. [3H]cAMP was purified on Dowex
and alumina columns as described previously (Qi et al., 2001a). For
assaysmeasuring inhibition of cAMP accumulation, cells were labeled
and treated as above, except that forskolin (either 10 or 30 mM, final
concentration) was included in the drug mixture to increase cAMP
levels. Reactionswere terminated and [3H]cAMP levels were quantified
as described above.
Intracellular Calcium Measurements. 1321N1 cells express-
ing GPR17 were grown on glass coverslips for 1–2 days to ∼20%
confluency. Prior to calciummeasurements, cells were incubated with
1 mM Fura-2/acetoxymethyl ester (Fura-2/AM) for 30–40 minutes.
Coverslips were then sealed in a Plexiglass chamber (200 ml total
volume) and mounted on the stage of Nikon Diaphot inverted
microscope (Nikon Instruments, Melville, NY). Cells were continuously
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superfused (1.4 ml/min) with HBSS with or without agonist. Solution
changes were accomplished by means of a manual valve attached to
a gravity-driven six-well reservoir. Cells were superfused with agonist
for 1 minute. Calcium responses were recorded with a digital imaging
system from Intracellular Imaging (Cincinnati, OH) as previously
described (Qi et al., 2001b).
RIA of Cell Surface Receptors. Cells were seeded in 24-well
plates at densities between 5  104 cells/well and 1  105 cells/well
and assayed 3 days later when confluent as described previously
(Qi et al., 2001b). Briefly, cells were fixed in 4% paraformaldehyde,
washed twice with HBSS containing Ca21 and Mg21 (HBSS11), and
blocked with medium containing 10% fetal bovine serum (FBS).
Cells were then incubated with a 1:1000 dilution of mouse anti-HA
monoclonal antibody (clone HA.11; Covance, Denver, PA) in medium
containing 5% FBS for 1 hour, washed twice with HBSS11, and then
incubated for 2 hours with 125I-labeled rabbit anti-mouse antibody in
medium containing 5% FBS. Cells were washed twice with HBSS11,
solubilized overnight with 1 M NaOH, and transferred to glass tubes
for quantification of radioactivity by g-counting.
Receptor Internalization. 1321N1 cells expressing HA-GPR17,
HA-P2Y2, or 3 HA-tagged CysLTR1 receptors were plated on glass
coverslips at 20% confluence and allowed to grow for 48 hours. The
cells were cooled to 4°C, labeled with mouse anti-HA antibody, and
washed to remove excess antibody. The temperature was then in-
creased to 37°C and the cells were treated with either phosphate-
buffered saline (all cells) or with 300 nM LTC4 (GPR17), 100 mMUTP
(P2Y2), 100 mMUDP (GPR17), or 100 mMUDP-glucose (GPR17) for 30
minutes. The cells were then fixed, permeabilized, and incubated with
AlexaFluor 488 goat anti-mouse antibody (Invitrogen/Molecular Probes,
Eugene, OR). Cells were imaged by confocal microscopy on an Olympus
Fluoview 300 laser scanning confocal imaging system (Olympus Imaging,
Center Valley, PA) configured with an IX70 fluorescence microscope
fitted with a PlanApo 60 oil objective.
Functional Regulation of CysLTR1 by GPR17. 1321N1 cells
were serially infected with retroviruses directing expression of 3
HA-tagged CysLTR1 and myc-tagged GPR17. Retroviruses directing
CysLTR1 expression conferred resistance to G418, while those directing
GPR17 expression conferred resistance to hygromycin. Cells expressing
either CysLTR1 alone or CysLTR1 and GPR17 were submitted to RIA to
determine the levels of CysLTR1 and challenged with LTC4 to quantify
receptor signaling as described above.
Results
Inhibition of cAMP Accumulation in C6, CHO, and
1321N1 Cells Stably Expressing GPR17. The orphan
GPCRGPR17was reported to be activated by uracil nucleotides
(UDP), nucleotide sugars (UDP-glucose and UDP-galactose),
and cysteinyl leukotrienes (LTC4 and leukotriene D4), and
coupled to both inhibition of cAMP accumulation and intra-
cellular Ca21 mobilization (Ciana et al., 2006; Pugliese et al.,
2009), although other studies have reported different agonist
selectivity (Benned-Jensen and Rosenkilde, 2010) or no acti-
vation of GPR17 by these ligands (Heise et al., 2000; Maekawa
et al., 2009). To investigate whether these compounds were
agonists at GPR17, HA-tagged GPR17 was stably expressed
in C6 and CHO cells by retroviral infection, and its capacity to
promote inhibition of cAMP accumulation was assessed. UDP,
UDP-glucose, and UDP-galactose (all at 100 mM) failed to
promote inhibition of cAMP in either C6 or CHO cells expres-
sing GPR17, regardless of whether cAMP levels were raised
by 10 or 30 mM forskolin (Fig. 1, A and C). The lack of activity
of these ligands was not due to the absence of GPR17 at the
plasma membrane, because GPR17 was well expressed at the
cell surface in both cell lines (Fig. 1E). In contrast, both UDP and
UDP-glucose decreased cAMPaccumulation by 65–75% inC6 and
CHO cells expressing the P2Y14 receptor, a Gi-coupled P2Y
receptor activated by UDP and UDP-sugars (Fig. 1, B and D)
(Carter et al., 2009). C6 cells natively express the P2Y12
receptor (Boyer et al., 1993), and therefore 2-methylthio-
ADP (2MeSADP) also significantly decreased cAMP accumula-
tion in C6 cells (Fig. 1B). Thus, activation of bona fide Gi-coupled
P2Y receptors, whether endogenously or recombinantly ex-
pressed, in two different cell lines markedly decreased cAMP
accumulation, whereas addition of the same ligands to C6 and
CHO cells expressing GPR17 had no effect on cAMP levels.
Activation of GPR17 also was reported to inhibit accumu-
lation of cAMP when expressed in 1321N1 cells (Ciana et al.,
2006; Daniele et al., 2011). Therefore, we also examined the
capacity of uracil nucleotides, UDP-sugars, and cysteinyl
leukotrienes to inhibit adenylyl cyclase in 1321N1 cells ex-
pressing GPR17. As in C6 and CHO cells, these compounds
had no effect on cAMP levels in cells preincubated with 10 or
30 mM forskolin, even though a cell surface RIA confirmed
robust expression of the receptor (data not shown).
Although HA-tagged receptors have been used routinely for
receptor studies without any effect on signaling, we consid-
ered whether the presence of an HA tag at the N terminus
interfered with receptor activity. Therefore, we stably expres-
sed wild-type GPR17 lacking the HA tag in CHO cells and
examined its capacity to inhibit cAMP accumulation. Similar
to the HA-tagged receptor, neither UDP nor UDP-glucose (both
at 100 mM) promoted inhibition of cAMP accumulation in
CHO cells expressing the nontagged GPR17 (data not shown).
Inositol Phosphate Accumulation in HEK293 and
COS-7 Cells Transiently Expressing GPR17 Alone or
with Gaq/i5. We also examined the capacity of GPR17 to
couple to Gi in HEK293 and COS-7 cells. For these experi-
ments, we used Gaq/i5, a chimeric Ga protein that couples
Gi-linked receptors to activation of PLC (Conklin et al., 1993).
HEK293 and COS-7 cells were transfected with GPR17 alone
or with Gaq/i5, and surface expression was verified by an
intact cell RIA (Fig. 2C). Neither UDP, UDP-glucose, UDP-
galactose (all at 100 mM), nor LTC4 (100 nM) promoted
inositol phosphate accumulation in cells transfected with
GPR17 alone or with Gaq/i5 (Fig. 2, A and B). In contrast, these
compounds promoted robust accumulation of [3H]inositol
phosphates in cells expressing their respective cognate re-
ceptors, i.e., UDP with P2Y6 receptors, UDP-glucose and
UDP-galactose with P2Y14 receptors (when coexpressed with
Gaq/i5), and LTC4 with CysLTR1 receptors (Fig. 2, A and B).
As reported in other studies (Lazarowski et al., 1995, 2003),
basal levels of inositol phosphates were significantly in-
creased in COS-7 cells expressing the P2Y6 or P2Y14
(cotransfected with Gaq/i5) (Fig. 2A) and in HEK293 cells
coexpressing the P2Y14 receptor with Gaq/i5 (Fig. 2B). This
increase ismost likely the result of cellular release of nucleotides
and nucleotide sugars, which activate their cognate receptors in
the absence of added agonists. In contrast, expression of GPR17
alone or with Gaq/i5 in either COS-7 or HEK293 cells had no
effect on basal levels of inositol phosphates.
Analysis of GPR17 Coupling to Other Ga Signaling
Pathways. Because no indication of GPR17 coupling to Gi
was observed, we examined whether GPR17 coupled to other
signaling pathways, i.e., Gq or G12/13. UDP, UDP-sugars, and
LTC4 had no effect on [3H]inositol phosphate accumulation
following transient expression of GPR17 in HEK293 and COS-
7 cells (Fig. 2A). To examine the capacity of stably expressed
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GPR17 to couple to Gq, 1321N1 and CHO cells expressing
GPR17 were challenged with UDP, UDP-sugars, or LTC4, and
inositol phosphate accumulation was measured. None of the
ligands tested stimulated inositol lipid hydrolysis above levels
observed inwild-type cells (Fig. 3, A andB). This was not due to
a lack of cell surface–expressed GPR17, as an intact cell RIA
showed that the receptor was well expressed in both cell lines
(Fig. 3C). In contrast, both carbachol, an agonist for endoge-
nous M3-muscarinic receptors in 1321N1 cells, and ATP, an
agonist for endogenous P2Y2 receptors in CHO cells, increased
inositol phosphate accumulation 2- to 3-fold over basal in the
respective cell lines (Fig. 3, A and B).
Fig. 1. UDP and UDP-glucose (UDP-Glu) do not promote inhibition of cAMP accumulation in C6 or CHO cells stably expressing GPR17. UDP-Glu or
UDP was added simultaneously with either 10 or 30 mM forskolin (Forsk), and the levels of cAMP accumulation were determined as described in
Materials and Methods. (A) C6 cells stably expressing GPR17; (B) C6 cells stably expressing the P2Y14 receptor; (C) CHO cells stably expressing GPR17;
(D) CHO cells stably expressing the P2Y14 receptor. (E) Cell surface levels of stably expressed HA-tagged GPR17 or P2Y14 receptors in C6 and CHO cells
were determined by an intact cell RIA. Data shown are representative assays performed three times with similar results. Ab, antibody; cpm, counts per
minute.
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We also examined the possibility that GPR17 couples to
G12/13 by cotransfecting COS-7 cells with pcDNA3-HA-GPR17
and pcDNA3-PLC-«. In this system, activated Ga12/13 inter-
acts with p115-RhoGEF, which in turn catalyzes the forma-
tion of GTP-bound RhoA and stimulation of PLC-« activity
(Hains et al., 2006). Neither UDP, UDP-glucose, nor LTC4
increased [3H]inositol phosphate accumulation in transfected
cells, whereas lysophosphatidic acid increased [3H]inositol
phosphate accumulation in COS-7 cells expressing the LPA1
receptor, which couples to Ga12/13, together with PLC-« (Fig. 4).
Moreover, the increase in [3H]inositol phosphate accumula-
tion promoted by LPA was markedly decreased in the
presence of the regulator of G protein signaling (RGS) domain
from p115RhoGEF, indicating that the increase was the result
of Ga12/13 and not from Gbg or Gaq.
Intracellular Ca21 Mobilization in 1321N1 Cells
Expressing GPR17. An additional observation in the study
by Ciana et al. (2006) was that UDP, UDP-glucose, and LTC4
resulted in intracellular Ca21 mobilization in a subset (30%)
of 1321N1 cells transfected with GPR17 but not with empty
vector. 1321N1 cells stably expressing GPR17 were seeded to
coverslips and loaded with Fura-2/AM to measure intracellu-
lar Ca21 mobilization promoted by the presumed agonists of
the receptor. When UDP, UDP-glucose, UDP-galactose (all
at 100 mM), or LTC4 (100 nM)) was superfused over 1321N1-
GPR17 cells, no Ca21 responses were observed in any of the.50
cells examined on four coverslips (Fig. 5). In contrast, 1 mM
carbachol (acting through an endogenous M3-muscarinic re-
ceptor) consistently promoted robust intracellular Ca21 mobi-
lization in 100% of 1321N1 cells examined (Fig. 5).
Internalization of Receptors in 1321N1 Cells. With
few exceptions, GPCRs internalize when challenged with
their cognate agonists. Therefore, as an additional measure
of agonist activity, we also examinedwhether any of the reported
agonists of GPR17 were capable of promoting internalization
of GPR17 in 1321N1 cells. 1321N1-GPR17, 1321N1-P2Y2, and
1321N1-CysLTR1 cells were incubated with anti-HA anti-
body at 4°C, the temperature was increased to 37°C, and
ligands were added to promote internalization of the receptors.
Addition of LTC4, UDP, or UDP-glucose to 1321N1-GPR17
cells for 30 minutes did not promote internalization of the
receptor, whereas LTC4 and UTP promoted marked internal-
ization of their cognate receptors in 1321N1-CysLTR1 and
1321N1-P2Y2 cells, respectively (Fig. 6).
GPR17 As a Negative Regulator of CysLTR1-Promoted
Signaling. Maekawa et al. (2009) reported that GPR17 was
not activated by UDP, UDP-sugars, or LTC4 in a number of cell
lines examined; instead, GPR17 was shown to inhibit CysLTR1
signaling, presumably through receptor dimer formation, with-
out any effect on cell surface expression of CysLTR1. Therefore,
we investigated the capacity of GPR17 to inhibit CysLTR1-
dependent signaling activity by infecting 1321N1 cells already
expressing HA-tagged CysLTR1 with retroviruses harboring
myc-tagged GPR17. LTC4 (300 nM) stimulated inositol phos-
phate accumulation was then measured in those cells express-
ing either CysLTR1 alone or CysLTR1 coexpressedwithGPR17.
LTC promoted a 3- to 4-fold increase in inositol phosphate ac-
cumulation in CysLTR1-expressing cells, but agonist-stimulated
response in cells coexpressing CysLTR1 with GPR17 was re-
duced by ∼85%. Importantly, the surface expression of LTR1
was reduced by 50% in cells coexpressing this GPCR with
GPR17 (Fig. 7). Transient transfection experiments with
Fig. 2. UDP, UDP-sugars, and LTC4 do not promote accumulation of
inositol phosphates in COS-7 or HEK293 cells transiently coexpressing
GPR17 and Gaq/i5. Application of UDP, UDP-glucose (UDP-Glu), UDP-
galactose (UDP-Gal) (all at 100 mM), and LTC4 (100 nM) all failed to
promote significant inositol phosphate accumulation in (A) COS-7 or (B)
HEK293 cells transfected with GPR17 alone or cotransfected with GPR17
and Gaq/i5, which links Gi/o-coupled receptors to the PLC signaling
pathway. In contrast, UDP, UDP-Glu, UDP-Gal, and LTC4 promoted
robust accumulation of inositol phosphates in cells expressing their
cognate receptors (UDP at P2Y6 receptors, UDP-Glu and UDP-Gal at
P2Y14 receptors, and LTC4 at CysLTR1 receptors). (C) Cell surface
expression of HA-tagged GPR17 was verified by an intact cell RIA. Data
shown are representative assays performed three times with similar
results. cpm, counts per minute.
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CysLTR1 and GPR17 gave similar results (data not shown).
These data are consistent with those reported by Maekawa
et al. (2009) showing that GPR17 is a negative regulator of
CysLTR1.
Discussion
Recent studies highlight the importance of GPR17 in in-
flammation, neuronal damage sensing, neurorepair, food in-
take, and myelination (Lecca et al., 2008; Chen et al., 2009;
Maekawa et al., 2010; Ren et al., 2012; Franke et al., 2013),
but the true identity of the endogenous agonists of the
receptor remains controversial. Ciana et al. (2006) reported
that GPR17 is activated by UDP, UDP-sugars, and cysteinyl
leukotrienes, whereas Benned-Jensen and Rosenkilde (2010)
reported activation of GPR17 with nucleotides but not with
leukotrienes. Heise et al. (2000) injected GPR17 cRNA into
Xenopus oocytes and also observed no response to LTC4 or
leukotriene D4, while these two compounds elicited strong
calcium-dependent chloride current in CysLTR2 cRNA–injected
oocytes. Maekawa et al. (2009) demonstrated that LTC4,
leukotriene D4, and leukotriene E4 were unable to promote
Ca21 mobilization in a variety of cell lines (1321N1, CHO,
and HEK293T) stably expressing the human or mouse
GPR17.
Data presented in this study show that neither UDP, UDP-
sugars, nor cysteinyl leukotrienes activate GPR17 when the
receptor is expressed stably in C6, 1321N1, and CHO cells
or transiently in COS-7 and HEK293 cells (with or without
Gaq/i5). In all cases, expression of GPR17 at the cell surface
was verified by an intact cell RIA (with the exception of ex-
periments with a nontagged receptor). Our studies extended
this question further by examining the potential coupling of
GPR17 to each of the G protein signaling pathways. Although
receptors known to couple to each G protein pathway
mediated predictable positive responses, no GPCR signaling
activity was observed in a variety of cells in response to nu-
cleotides or leukotrienes. Receptor activation was measured
by inhibition of cAMP accumulation, inositol phosphate pro-
duction, and by monitoring Ca21 mobilization with Fura-2/AM.
None of the purported ligands of GPR17 activated the receptor
in any of these test systems, whereas the cognate receptors
for these ligands showed robust signaling activity. We also
demonstrated that these ligands failed to promote internaliza-
tion of GPR17 in 1321N1 cells, whereas receptors that are
activated by these compounds were markedly internalized.
Based on these data, we conclude that UDP, UDP-sugars, and
cysteinyl leukotrienes are not activators of GPR17.
Maekawa et al. (2009) also reported that coexpression of
GPR17 with CysLTR1 in 1321N1 cells significantly inhibited
LTC4- and LTD4-promoted calcium influx and extracellular
signal–regulated kinase phosphorylation compared with the
response in cells expressing the CysLTR1 receptor alone. Be-
cause GPR17 coexpression did not affect surface expression of
the CysLTR1 receptor, the authors concluded that GPR17
functions as a negative regulator of the CysLTR1 receptor.
A more recent study has shown that knockout of GPR17 in
mice increased the immune responses to dust mites, including
the recruitment of inflammatory cells, increased levels of IgE,
and increased Th2 and Th17 cytokine expression, which was
due to the absence of inhibition of CysLTR1 signaling activity
by GPR17 (Maekawa et al., 2010). We also observed a marked
decrease (.80%) in CysLTR1 receptor activity when GPR17
was coexpressed, although we also saw a decrease in the level
of CysLTR1 at the cell surface (∼50%). Given that CysLTR1
was expressed recombinantly, it is likely that the levels of
receptors, although decreased, are more than sufficient for
full activity and that the decrease in receptor signaling is
a direct consequence of GPR17 coexpression. Thus, our data
are fully consistent with those of Maekawa et al. (2009, 2010).
We are unsure why some laboratories have shown activity
of UDP, UDP-sugars, and LTC4 at GPR17 whereas others
(including ours) have not observed activity of some or all these
ligands. Early characterization of GPR17 mostly focused on
Fig. 3. Lack of uracil nucleotide– and cysteinyl leukotriene–promoted
accumulation of inositol phosphates in 1321N1 or CHO cells stably
expressing GPR17. UDP, UDP-glucose (UDP-Glu), UDP-galactose (UDP-
Gal) (all at 100 mM), or LTC4 (100 nM) failed to promote significant
accumulation of inositol phosphates in (A) 1321N1 or (B) CHO cells stably
expressing GPR17 compared with cells expressing the empty vector. (C)
Cell surface expression of HA-tagged GPR17 was verified by an intact cell
RIA. Data shown are from a representative assay performed three times
with similar results. Ab, antibody; cpm, counts per minute; WT, wild type.
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guanosine 59-3-O-(thio)triphosphate binding studies instead
of second messenger assays, but a recent study of GPR17 by
the authors who originally reported activity of these ligands
at the receptor showed inhibition of cAMP accumulation and
receptor internalization in 1321N1 cells (Daniele et al., 2011).
However, using the same conditions (cAMP levels elevated by
10 mM forskolin) and the same cells (1321N1), we failed to
observe inhibition of cAMP accumulation in over a dozen in-
dependent experiments, even though the receptor was ex-
pressed at the cell surface based on an intact cell RIA.
We also examined the sequence of GPR17 in our clones to
confirm that its sequence matched the sequence in GenBank.
Surprisingly, of the six sequences in GenBank, two of them
(accession numbers AAH31653.1 and BAG54380.1) harbored
amino acid differences from the other four. AAH31653.1 contains
an L55F mutation, while BAG54380.1 has three mutations:
L44P, V225A, and S287R. Our sequence was identical to the
other four sequences and matched the sequence reported in
Ciana et al. (2006).
A recent study by a different group analyzed the pharma-
cological selectivity of GPR17 expressed in HEK293 cells using
the GloSensor cAMP assay (Promega, Madison, WI) and ob-
served activation by UDP, UDP-galactose, and UDP-glucose
(Buccioni et al., 2011). However, the authors were unable to
demonstrate inhibition of cAMP accumulation by two different
immunocompetitive cAMP assays and required the increased
sensitivity of the GloSensor assay to observe inhibition of
adenylyl cyclase. In contrast, Daniele et al. (2011) reported
robust inhibition of cAMP accumulation in 1321N1 cell using
a competitive protein-binding assay. Thus, there are important
discrepancies even among laboratories that observe activa-
tion of GPR17with nucleotides and nucleotide sugars.We tested
four different cell lines for inhibition of cAMP accumulation,
Fig. 4. GPR17 does not couple to G12/13 signaling pathways. Cotransfec-
tion of the LPA1 receptor with PLC-« (activated by Ga12/13) in COS-7 cells
markedly increased LPA-promoted inositol phosphate accumulation,
which was blocked by cotransfection of the RGS domain from p115Rho-
GEF. In contrast, LTC4 (100 nM) failed to promote significant inositol
phosphate accumulation in COS-7 cells transfected with GPR17 or cotrans-
fected with GPR17 and PLC-«. GPR17-expressing cells were stimulated with
300 nM LTC4 (agonist, for 30 minutes), and all others were challenged with
10 mM LPA. Data shown are from a representative assay performed three
times with similar results. cpm, counts per minute.
Fig. 5. Lack of uracil nucleotide– and leukotriene-promoted intracellular Ca2+ mobilization in 1321N1-GPR17 cells. GPR17-expressing 1321N1 cells
were grown on glass coverslips to a density of 20% of confluence. Cells were placed in a sealed chamber and continuously superfused with HBSS with or
without (A) 100 mM UDP, (B) 100 mM UDP-glucose (UDP-Glu), (C) 100 mM UDP-galactose (UDP-Gal), (D) 100 nM LTC4, or (A–D) 1 mM carbachol
(Carb). Each compound was superfused for 1 minute. Traces of intracellular Ca2+ concentrations were averaged from 6–9 individual cells/coverslip. Each
compound was tested on a minimum of three coverslips.
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including transfection experiments with Gaq/i5, but observed
no agonist-dependent activity.
Identification and characterization of new P2Y receptors
has been fraught with controversy and misidentification. At
least part of the difficulty in identifying new P2Y receptors is
the lack of sequence identity between known P2Y receptors;
the two P2Y receptor subfamilies, P2Y1 and P2Y12, share
minimal sequence identity (∼20%), and thus low homology of
an orphan receptor to known P2Y receptors is not a criterion
for exclusion. P2Y receptors are found in nearly all cell lines
(with the exception of 1321N1 cells), and contribution of endo-
genous receptors to the signal supposedly emanating from
an expressed recombinant one is often difficult to exclude.
Finally, the possibility of hetero-oligomerization of an orphan
receptor with endogenous P2Y receptors (including receptors
that are not normally expressed or are expressed at low levels
but are “recruited” to the cell surface by expression of the
orphan receptor) also could lead to potentially incorrect identifi-
cation (see, e.g., Bush et al., 2007).
Because of nucleotide release and/or cell lysis, basal levels
of inositol phosphates in COS-7 cells transfected with P2Y
receptors are consistently observed to be elevated over vector-
transfected controls (Lazarowski et al., 1995, 2003). For ex-
ample, both the P2Y6 receptor alone and the P2Y14 receptor
cotransfected with Gaq/i5 result in elevated basal levels of
inositol phosphates in COS-7 cells compared with cells trans-
fected with empty vector (Fig. 2). In contrast, basal levels of
[3H]inositol phosphates in COS-7 (or HEK293) cells expressing
GPR17 either alone or with Gaq/i5 were not significantly higher
than vector-transfected cells (Fig. 2, A and B). These data suggest
that neither UDP nor UDP-sugars released into the medium
of cells are capable of activating GPR17, although they do
increase the activation of their cognate receptors, P2Y6 and
P2Y14. These results are consistent with the lack of activity
of nucleotides and nucleotide sugars at GPR17.
Even though nucleotides are unlikely to activate CysLTR1,
there does appear to be a function interaction between
CysLTR1 and P2Y receptors. For example, activation of
endogenous P2Y receptors in U937 cells with ATP or UDP
strongly cross-desensitized CysLTR1 receptors, but not vice
versa, and a similar cross-desensitization was observed in
COS-7 cells exogenously expressing CysLTR1 (Capra et al.,
2005). This heterologous desensitization was dependent on
protein kinase C, because GF109203X (bisindoylmaleimide I)
blocked nucleotide-dependent desensitization of CysLTR1.
A separate study demonstrated that antagonists of leukotri-
ene receptors, montelukast and pranlukast, inhibit nucleotide-
promoted activation of P2Y receptors both in differentiated
U937 cells and in 1321N1 cells stably expressing P2Y1, P2Y2,
P2Y4, or P2Y6 receptors (Mamedova et al., 2005). This
antagonism was not competitive, however, as high concentra-
tions of nucleotides were unable to surmount the inhibition,
and these antagonists did not block binding of the P2Y1
receptor–selective antagonist [3H]MRS2279 [2-chloro-N6-methyl-
(N)-methanocarba-29-deoxyadenosine-39,59-bisphosphate] to the
P2Y1 receptor.
Fig. 6. Neither UDP, UDP-glucose (UDP-G), nor LTC4 pro-
motes internalization of GPR17 stably expressed in 1321N1
cells. 1321N1 cells stably expressing CysLTR1, P2Y2, or
GPR17 receptors were seeded on glass coverslips for 2 days,
then cooled down to 4°C and labeled with mouse monoclonal
anti-HA.11 antibody for 1 hour. Cells were washed, warmed
to 37°C, and treated with either phosphate-buffered saline
(PBS) or receptor agonists (100 mMUTP, UDP, or UDP-G or
100 nM LTC4) for 30 minutes. The cells were then fixed,
permeabilized, and stained with goat anti-mouse A-488 se-
condary antibody. Localization of receptors was determined
by confocal microscopy.
Fig. 7. GPR17 negatively regulates CysLTR1 function. 1321N1 cells stably expressing 3 HA-tagged CysLTR1 were infected with retroviruses
directing expression of myc-tagged GPR17, and the resulting cells were assessed for LTC4-promoted inositol phosphate accumulation (A) and CysLTR1
expression by a cell surface RIA (B). Data shown are from a representative assay performed three times with similar results. Ab, antibody; cpm, counts
per minute.
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In conclusion, our data demonstrate that nucleotides, nucle-
otide sugars, and cysteinyl leukotrienes do not promote activation
of GPR17 when assessed by standard and well established
signaling assays. Although the reasons for the discrepancies
between different laboratories are unclear, our data are con-
sistent with an earlier study showing that GPR17 is a negative
regulator of CysLTR1 function.
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